Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOGNASDAQ:ACRVNASDAQ:ALECNASDAQ:INMB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$9.30+1.1%$8.29$3.75▼$11.40$148.99M2.7397,144 shs10,139 shsACRVAcrivon Therapeutics$1.36+10.7%$1.27$1.05▼$10.16$42.79M1.63266,441 shs194,279 shsALECAlector$1.55+9.2%$1.33$0.87▼$6.78$152.49M0.74833,182 shs93,500 shsINMBINmune Bio$2.26+7.9%$7.21$1.89▼$11.64$51.36M1.34744,078 shs2.22 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition-1.39%+3.49%-2.13%+81.10%+919,999,900.00%ACRVAcrivon Therapeutics+3.36%-0.81%+11.82%-29.31%-79.01%ALECAlector+1.43%-4.70%+5.58%+20.34%-67.87%INMBINmune Bio-9.52%-68.38%-71.98%-74.10%-75.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACOGAlpha Cognition2.0769 of 5 stars3.50.00.00.03.60.80.0ACRVAcrivon Therapeutics2.7974 of 5 stars3.52.00.00.02.72.50.6ALECAlector4.0961 of 5 stars3.13.00.04.52.72.50.0INMBINmune Bio1.5848 of 5 stars3.30.00.00.02.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$20.00115.05% UpsideACRVAcrivon Therapeutics 3.00Buy$17.711,201.56% UpsideALECAlector 2.14Hold$4.00158.06% UpsideINMBINmune Bio 2.57Moderate Buy$22.80911.09% UpsideCurrent Analyst Ratings BreakdownLatest ACRV, ALEC, ACOG, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025INMBINmune BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral7/1/2025INMBINmune BioScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Outperform ➝ Sector Underperform6/30/2025INMBINmune BioRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold5/16/2025ACOGAlpha CognitionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/16/2025ACRVAcrivon TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/15/2025ACRVAcrivon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.005/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.005/5/2025ACRVAcrivon TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$6.005/4/2025ACRVAcrivon TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha CognitionN/AN/AN/AN/A$2.59 per shareN/AACRVAcrivon TherapeuticsN/AN/AN/AN/A$5.68 per shareN/AALECAlector$100.56M1.54N/AN/A$1.29 per share1.20INMBINmune Bio$10K5,181.99N/AN/A$1.45 per share1.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$14.64M-$1.20N/A∞N/AN/A-65.83%-48.21%8/11/2025 (Estimated)ACRVAcrivon Therapeutics-$80.56M-$2.22N/AN/AN/AN/A-44.66%-40.94%8/12/2025 (Estimated)ALECAlector-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)INMBINmune Bio-$42.08M-$1.93N/AN/AN/AN/A-119.35%-89.37%7/30/2025 (Estimated)Latest ACRV, ALEC, ACOG, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ACOGAlpha Cognition-$0.58-$0.20+$0.38-$0.13$0.50 million$2.93 million5/13/2025Q1 2025ACRVAcrivon Therapeutics-$0.57-$0.51+$0.06-$0.51N/AN/A5/8/2025Q1 2025INMBINmune Bio-$0.43-$0.43N/A-$0.43N/A$0.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/AACRVAcrivon TherapeuticsN/AN/AN/AN/AN/AALECAlectorN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A17.1416.83ACRVAcrivon TherapeuticsN/A11.1711.17ALECAlector0.103.343.34INMBINmune BioN/A2.642.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/AACRVAcrivon Therapeutics71.62%ALECAlector85.83%INMBINmune Bio12.72%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%ACRVAcrivon Therapeutics8.50%ALECAlector9.10%INMBINmune Bio35.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A16.02 million13.78 millionN/AACRVAcrivon Therapeutics5831.35 million28.69 millionNot OptionableALECAlector27099.99 million90.89 millionOptionableINMBINmune Bio1022.98 million14.78 millionOptionableACRV, ALEC, ACOG, and INMB HeadlinesRecent News About These CompaniesINmune slides again as Scotiabank, RJ cut ratings after Alzheimer’s drug miss2 hours ago | au.finance.yahoo.comScotiabank Downgrades INmune Bio (INMB)2 hours ago | msn.comINmune Bio: What's Left For Investors2 hours ago | seekingalpha.comINmune Bio (NASDAQ:INMB) Rating Lowered to Hold at Raymond James Financial4 hours ago | marketbeat.comAlzheimer's trial misses goal, but subgroup result offers path forwardJuly 1 at 10:38 AM | thepharmaletter.comTINmune Bio (NASDAQ:INMB) Lowered to "Neutral" Rating by BTIG ResearchJuly 1 at 8:25 AM | marketbeat.comINmune Bio (NASDAQ:INMB) Lowered to Sector Underperform Rating by ScotiabankJuly 1 at 8:25 AM | marketbeat.comXpro phase II miss as Inmune’s Mindful tunes in to AD subgroupJuly 1 at 5:37 AM | bioworld.comBINmune Bio stock plummets after mixed Phase 2 Alzheimer’s trial resultsJuly 1 at 5:37 AM | finance.yahoo.comINmune Bio fails to meet main goal in Alzheimer's treatment studyJuly 1 at 5:37 AM | msn.comINmune Bio's Alzheimer's drug falls short of mid-stage study goal, shares tumbleJuly 1 at 5:37 AM | finance.yahoo.comINmune Bio slumps on midstage fail for Alzheimer's drugJuly 1 at 5:37 AM | pharmaphorum.comPINmune Bio Shares Collapse After Mixed Results from Alzheimer’s Drug TrialJuly 1 at 5:37 AM | msn.comINmune Bio's Alzheimer's drug misses mid-stage goal, shares sink to record lowJuly 1 at 5:37 AM | msn.comINmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJune 30 at 4:05 PM | globenewswire.comINmune Bio shares tumble as Alzheimer's drug falls short in mid-stage trialJune 30 at 12:56 PM | proactiveinvestors.comINmune Bio's Alzheimer's drug fails to meet main goal in mid-stage studyJune 30 at 7:36 AM | reuters.comINmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's DiseaseJune 30 at 7:30 AM | globenewswire.comINmune Bio's US$24m Market Cap Fall Books Insider LossesJune 28, 2025 | finance.yahoo.comINmune Bio Inc. (INMB) Stock Price Today - WSJJune 28, 2025 | wsj.comINmune Bio Stock Price, Quotes and Forecasts | NASDAQ:INMB - BenzingaJune 28, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACRV, ALEC, ACOG, and INMB Company DescriptionsAlpha Cognition NASDAQ:ACOG$9.30 +0.10 (+1.09%) As of 10:39 AM EasternAlpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Acrivon Therapeutics NASDAQ:ACRV$1.36 +0.13 (+10.65%) As of 11:02 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Alector NASDAQ:ALEC$1.55 +0.13 (+9.15%) As of 11:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.INmune Bio NASDAQ:INMB$2.26 +0.17 (+7.89%) As of 11:02 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Why Realty Income’s 5.59% Yield Makes It a Must-Buy REIT Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
